Antidepressant use in low- middle- and high-income countries: a world mental health surveys report

dc.contributor.authorKadzin, A. E.
dc.contributor.authorWu, C.
dc.contributor.authorHwang, I.
dc.contributor.authorPuac-Polanco, V.
dc.contributor.authorSampson, N. A.
dc.contributor.authorAl-Hamzawi, A.
dc.contributor.authorAlonso, J.
dc.contributor.authorAndrade, L. H.
dc.contributor.authorBenjet, C.
dc.contributor.authorCaldas-de-Almeida, J.
dc.contributor.authorde Girolamo, G.
dc.contributor.authorde Jonge, P.
dc.contributor.authorFlorescu, S.
dc.contributor.authorGureje, O.
dc.contributor.authorHaro, J. M.
dc.contributor.authorHarris, M. G.
dc.contributor.authorKaram, E. G.
dc.contributor.authorKaram, G.
dc.contributor.authorKovess-Masfety, V.
dc.contributor.authorLee, S.
dc.contributor.authorMcGrath, J. J.
dc.contributor.authorNavarro-Mateu, F.
dc.contributor.authorNishi, D.
dc.contributor.authorOladeji, B. D.
dc.contributor.authorPosada-Villa, J.
dc.contributor.authorStein, D. J.
dc.contributor.authorÜstün, T. B.
dc.contributor.authorVigo, D. V.
dc.contributor.authorZarkov, Z.
dc.contributor.authorZaslavsky, A. M.
dc.contributor.authorKessler, R. C.
dc.contributor.authorWHO World Mental Health Survey collaborators
dc.date.accessioned2026-04-10T14:00:50Z
dc.date.issued2021
dc.description.abstractBackground. The most common treatment for major depressive disorder (MDD) is antidepressant medication (ADM). Results are reported on frequency of ADM use, reasons for use, and perceived effectiveness of use in general population surveys across 20 countries. Methods. Face-to-face interviews with community samples totaling n = 49 919 respondents in the World Health Organization (WHO) World Mental Health (WMH) Surveys asked about ADM use anytime in the prior 12 months in conjunction with validated fully structured diagnostic interviews. Treatment questions were administered independently of diagnoses and asked of all respondents. Results. 3.1% of respondents reported ADM use within the past 12 months. In high-income countries (HICs), depression (49.2%) and anxiety (36.4%) were the most common reasons for use. In low- and middle-income countries (LMICs), depression (38.4%) and sleep problems (31.9%) were the most common reasons for use. Prevalence of use was 2–4 times as high in HICs as LMICs across all examined diagnoses. Newer ADMs were proportionally used more often in HICs than LMICs. Across all conditions, ADMs were reported as very effective by 58.8% of users and somewhat effective by an additional 28.3% of users, with both proportions higher in LMICs than HICs. Neither ADM class nor reason for use was a significant predictor of perceived effectiveness. Conclusion. ADMs are in widespread use and for a variety of conditions including but going beyond depression and anxiety. In a general population sample from multiple LMICs and HICs, ADMs were widely perceived to be either very or somewhat effective by the people who use them.
dc.identifier.issn0033-2917
dc.identifier.issn1469-8978
dc.identifier.otherui_art_kadzin_antidepressant_2023
dc.identifier.otherPsychological Medicine 53(4), pp. 1583-1591
dc.identifier.urihttps://repository.ui.edu.ng/handle/123456789/13631
dc.language.isoen
dc.publisherCambridge University Press
dc.subjectAntidepressant medications
dc.subjectperceived effectiveness
dc.subjectreasons for use
dc.titleAntidepressant use in low- middle- and high-income countries: a world mental health surveys report
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
(50) ui_art_kadzin_antidepressant_2023.pdf
Size:
295.64 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.61 KB
Format:
Item-specific license agreed upon to submission
Description: